Pharma-Bio Serv Reports First Quarter 2026 Results: Returns to Profitability Despite Revenue Dip
DORADO, PUERTO RICO, March 17, 2026 — Pharma-Bio Serv, Inc. (OTCQB: PBSV), a leading compliance, project management, and technology transfer support consulting firm for the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food, and allied products industries, has announced its financial results for the quarter ended January 31, 2026.
Key Financial Highlights
- Revenue: The company reported revenues of approximately \$2.3 million for the quarter, representing a decrease of roughly \$0.2 million compared to the same period last year.
- Net Income: Net income for the quarter was \$32,860, marking a significant improvement of \$24,324 over the prior-year quarter, when the company reported a slight loss.
Strategic and Operational Updates
- Management stated that the fiscal year began with a strong focus on executing strategic priorities, including sharpening the company’s service portfolio, reinforcing operational alignment, and concentrating efforts on markets where Pharma-Bio Serv’s capabilities create the most value.
- The company attributed the return to profitability to improvements in operational efficiency, disciplined cost management, and stronger alignment with high-opportunity markets.
CEO’s Commentary
“We are encouraged by the progress made in improving operational efficiency, which allowed us to deliver a modest profit compared to a slight loss in the same period last year. As we look ahead, we will continue strengthening client relationships, maintaining disciplined cost management, and aligning our organization with the areas of greatest opportunity. We remain confident that these efforts position us well to build momentum and deliver long-term value to our shareholders,” said Mr. Sanchez, Chief Executive Officer.
About Pharma-Bio Serv
Pharma-Bio Serv provides regulatory compliance consulting and related services to clients in Puerto Rico, the U.S., Europe, and Latin America. Its core business is focused on FDA and international agency regulatory compliance. The company’s global team comprises leading engineering and life science professionals, as well as quality assurance managers and directors.
Potential Price-Sensitive Information for Shareholders
- Return to Profitability: After a period of losses, the company’s move back into profitability—even with slightly lower revenues—signals improved operational efficiency and cost management. This is a potentially positive indicator for future performance and could influence investor sentiment.
- Strategic Focus: The management’s commitment to focusing resources on areas with the highest potential returns and ongoing operational improvements may signal further financial improvements in the coming quarters.
- Cost Management: Disciplined cost management, if sustained, can help preserve margins even in challenging revenue environments.
- Forward-Looking Statements: The company specifically cautions that forward-looking statements are subject to significant business and economic risks. Investors are advised to review the “Risk Factors” detailed in the latest 10-K filing for a comprehensive understanding of the company’s risk profile.
Contact Information
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787-278-2709
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated. Investors should review the company’s filings with the Securities and Exchange Commission and consult their financial advisors before making any investment decisions.
View Pharma-Bio Serv, Inc. Historical chart here
